TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

Rhea-AI Summary

TRACON Pharmaceuticals (NASDAQ: TCON) announced that CEO Charles Theuer will participate in a fireside chat at the Jefferies London Virtual Healthcare Conference on November 18-19, 2021. The chat will be available on-demand starting at 3:00 AM Eastern Time on November 18, 2021, accessible via the Company’s website. TRACON focuses on developing targeted cancer therapies utilizing a CRO-independent platform. Key products include Envafolimab, YH001, TRC102, and TJ004309, with ongoing corporate partnerships for U.S. regulatory and clinical development.

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

The fireside chat will be available on-demand beginning at 3:00 AM Eastern Time on Thursday, November 18, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Brian Ritchie
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	(212) 915-2578
mwiggins@traconpharma.com	britchie@lifesciadvisors.com

 

FAQ

When will TRACON Pharmaceuticals' CEO participate in the Jefferies London Virtual Healthcare Conference?

CEO Charles Theuer will participate in the conference on November 18-19, 2021.

How can I access the fireside chat with TRACON's CEO?

The fireside chat will be available on-demand on November 18, 2021, starting at 3:00 AM Eastern Time on TRACON's website.

What are the key products in TRACON Pharmaceuticals' pipeline?

TRACON's pipeline includes Envafolimab, YH001, TRC102, and TJ004309, targeting various cancer treatments.

What is TRACON Pharmaceuticals' approach to product development?

TRACON utilizes a cost-efficient, CRO-independent product development platform to partner with ex-U.S. companies.

What is the significance of the Jefferies London Virtual Healthcare Conference for TCON?

It provides a platform for TRACON to share updates on its cancer therapies and business strategy with investors.